Today
-0.55%
5 Days
-1.55%
1 Month
-4.44%
6 Months
-5.07%
Year to Date
+4.52%
1 Year
+13.54%
• Morgan Stanley faced downward pressure from macroeconomic crosscurrents and profit-taking. • Underwriting delays and M&A hesitancy caused cautious advisory fee modeling. • Morgan Stanley reported an annual revenue of $114.74 billion.
• Morgan Stanley shares rose following the U.S. midterm elections and broader market rallies. • Third-quarter results showed strong equities trading and record wealth management net revenues. • Analysts rate the stock as Buy with an average price target of $213.90.
• CME Group reported record quarterly revenue despite elevated operational expenses and lower trading volumes. • Regulatory delays for strategic product expansions slowed near-term revenue catalysts for the company. • Technical indicators show a MACD buy signal and a neutral RSI condition.
• Morgan Stanley reported third-quarter net revenues of $20.34 billion and EPS of $3.03. • Institutional equity trading revenue surged 41 percent year over year to $5.8 billion. • Wealth management achieved record net revenues of $9.1 billion and total client assets.
• Morgan Stanley reported third-quarter revenue of $114.74B and net profit of $16.25B. • Analysts rate the stock as Buy with an average price target of $216.00. • The Williams %R indicates a buy condition with a value of 37.296.
• Morgan Stanley beat third-quarter revenue and earnings expectations. • Fixed income trading and investment management revenues contracted. • Technical indicators show sell signals and oversold conditions.
Morgan Stanley Q3 2026 Earnings Call: Record Wealth Flows and Equities Growth


| Shareholders | Proportion |
|---|---|
| Mitsubishi UFJ Financial Group Inc | 24.11% |
| State Street Investment Management (US) | 6.58% |
| Vanguard Capital Management, LLC | 4.93% |
| BlackRock Institutional Trust Company, N.A. | 3.86% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 32.88% |
| Holding Company | 24.15% |
| Investment Advisor/Hedge Fund | 21.67% |
| Research Firm | 2.47% |
Related Instruments